



Graphene-based nanosheets for delivery of chemotherapeutics and biological drugs☆



Gayong Shim¹, Mi-Gyeong Kim¹, Joo Yeon Park, Yu-Kyoung Oh^{*}

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea

ARTICLE INFO

Article history:

Received 15 January 2016

Received in revised form 17 March 2016

Accepted 7 April 2016

Available online 13 April 2016

Keywords:

Graphene-based nanosheets

Drug delivery

Chemotherapeutics

Biological drugs

Surface modification

Targeting ligands

ABSTRACT

Graphene-based nanosheets (GNS), including graphenes, graphene oxides and reduced graphene oxides, have properties suitable for delivery of various molecules. With their two-dimensional structures, GNS provide relatively high surface areas and capacity for non-covalent π - π stacking and hydrophobic interactions with various drug molecules. Currently, GNS-based delivery applications extend to chemotherapeutics as well as biological drugs, including nucleic acid drugs, proteins, and peptides. Surfaces of GNS have been modified with various polymers, such as polyethylene glycol and biopolymers, which enhance biocompatibility and increase drug loading. Anticancer drugs are prominent among chemotherapeutic agents tested, and have been loaded onto GNS with relatively high loading capacities compared with other nanocarriers. For enhanced distribution to specific tissues, GNS have been covalently or non-covalently modified with targeting ligands, including folic acid, transferrins, and others. In this review, we cover the current status of GNS for delivery of anticancer chemotherapeutics and biological drugs, with a focus on nucleic acid drugs. Remaining challenges for the application of GNS for drug-delivery systems and future perspectives are also addressed.

© 2016 Published by Elsevier B.V.

Contents

1. Introduction	206
2. Physicochemical properties of GNS for drug delivery	206
2.1. Interaction with drug molecules	206
2.2. Quenching of fluorescent drugs	208
3. Surface modification to enhance biocompatibility	208
3.1. Modification with synthetic polymers	208
3.1.1. Modification with PEG	208
3.1.2. Modification with other polymers	209
3.2. Modification with natural polysaccharides	209
3.3. Modification with proteins	210
3.4. Modification with phospholipids	210
4. GNS for delivery of chemotherapeutics	210
4.1. Anthracycline antitumor antibiotics	210
4.2. Anticancer quinoline alkaloids	212
4.3. Taxanes	212
4.4. Platinum complexes	212
4.5. Nitrosourea compounds	212
4.6. Pyrimidine analogs	213
4.7. Polyphenolic compounds	213
4.8. Quinone compounds	213
4.9. Other chemotherapeutics	213
4.9.1. Methotrexate	213
4.9.2. Lucanthone	213
4.10. Co-delivery of anticancer drugs with photosensitizers	213

☆ This review is part of the *Advanced Drug Delivery Reviews* theme issue on "Graphene-based materials in nanomedicine".

* Corresponding author. Tel.: +82 2 880 2493; fax: +82 2 882 2493.

E-mail address: ohyk@snu.ac.kr (Y.-K. Oh).

¹ These authors equally contributed to this work.

5.	GNS for delivery of biological drugs	214
5.1.	Delivery of plasmid DNA	214
5.2.	Delivery of siRNA	216
5.3.	Delivery of protein and peptide drugs	217
6.	Targeting moieties for GNS	218
6.1.	Small chemicals	218
6.2.	Monoclonal antibodies and aptamers	220
6.2.1.	Integrin $\alpha v \beta_3$ antibody	220
6.2.2.	CD20 antibody	220
6.2.3.	Protein tyrosine kinase 7-specific aptamer	220
6.3.	Proteins and peptides	220
6.3.1.	Transferrin	220
6.3.2.	Vascular endothelial growth factor-121	221
6.3.3.	RGD peptide	221
6.3.4.	NGR peptide	221
6.4.	Polysaccharides	221
7.	Pharmacokinetics and biodistribution	221
8.	Current challenges and future perspectives	223
	Acknowledgment	224
	References	224

1. Introduction

Graphene is a kind of carbon allotrope, exemplified by fullerenes and carbon nanotubes, with a flat single layer of graphite containing stacked layers of carbon atoms with a honeycomb lattice [1]. Graphene is reported to have various extraordinary properties, including a unique structure and mechanical, thermal, and optical characteristics [2,3]. Graphene-based nanosheets (GNS) with nanoscale lateral sizes include graphene nanosheets [4] (Fig. 1A), graphene oxide (GO) nanosheets [5] (Fig. 1B), and reduced graphene oxide (rGO) nanosheets [6] (Fig. 1C). GNS have been intensively exploited as nanocarriers for a variety of drugs, including chemicals [7] and biological drugs [8]. GNS in particular have been proposed as a potential nanocarrier of water-insoluble anti-cancer chemotherapeutics [9,10].

Although the initial physical exfoliation method for preparing graphene single layers—a novel approach using adhesive tape—was very simple, its applicability to large-scale, industrial production of graphene layers is limited [11]. Therefore, chemical exfoliation methods, including oxidation of graphite resulting in GO and rGO [12, 13], have become more commonly used for bulk scale production. GO can be dispersed as a single layer in water owing to the hydroxyl (—OH), epoxide (—O—), and carboxylic acid (COOH) functional groups on their surface and edges, but this impairs the planar hydrophobic structure of the graphene surface, resulting in the loss of its intrinsic properties. Reduction of GO to produce rGO restores a surface that mimics the original planar graphene layer with carboxyl groups on their edges [6].

In this review, we provide an overview of significant advances in graphene-based nanomaterials for delivery of chemical and biological drugs, address current challenges, and highlight future perspectives.

2. Physicochemical properties of GNS for drug delivery

2.1. Interaction with drug molecules

Among the various types of delivery systems, GNS features a unique two-dimensional planar surface. This two-dimensional feature of GNS confers a higher capacity for drug loading than other types of drug-delivery systems [14]. GO and rGO have been more extensively studied for delivery of drugs than pure graphene. The relative paucity of studies on graphene nanosheets for drug delivery likely reflects the poor water dispersity of these nanosheets. Graphene nanosheets are composed of sp²-hybridized carbon in a honeycomb lattice with nanoscale lateral sizes. Aksay and colleagues reported that the mean thickness of a stack of 140 graphene sheets was ~1.75 nm [14]. The surface area of graphene as a dry powder, measured by the Brunauer–Emmett–Teller method, has been found to be 600–900 m²/g [14]. Although the high surface area of graphene nanosheets makes it possible to load drugs with high capacity, the hydrophobicity of these nanosheets and difficulties associated with handling them present limitations to their application in drug delivery. Because they lack functional groups on their surfaces [4], pure graphene nanosheets mainly interact with drug molecules through π - π stacking and hydrophobic interactions.




Fig. 1. Structures of GNS. Structures of graphene (A)[4], GO (B)[5], and rGO (C)[6] are presented.

Download English Version:

<https://daneshyari.com/en/article/5520010>

Download Persian Version:

<https://daneshyari.com/article/5520010>

[Daneshyari.com](https://daneshyari.com)